This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van de Velde, H. J.K. Articles by Bayssas, M. Search for Related Content PubMed PubMed Citation Articles by van de Velde, H. J.K. Articles by Bayssas, M.

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

From Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium and Raritan NJ, USA

Correspondence: Helgi J.K. van de Velde, Johnson & Johnson Parmaceutical Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium. E-mail: hvdvelde{at}prdbe.jnj.com

There are a number of reports in literature data on the long-term outcomes of patients with multiple myeloma treated with high-dose therapy and autologous stem cell transplantation (HDT/SCT). While in general these data support the association between maximal tumor response and overall survival or progression-free survival after HDT/SCT, some trials have failed to find such correlation and there is no recent comprehensive literature analysis of this issue. We, therefore, performed a comprehensive literature review to identify prospective and retrospective studies on HDT/SCT in frontline multiple myeloma in which long-term outcomes were reported according to best tumor response observed. Following a prospectively defined search strategy we identified 21 studies (10 prospective and 11 retrospective studies) in which outcomes of 4,990 HDT/SCT patients according to their best tumor response were reported. The majority of these studies indicated a correlation between maximal response during or after HDT/SCT and long-term outcomes (overall survival and event-free/progression-free survival). The conclusions in individual studis report on the association between maximal response following induction therapy and long-term outcomes were more heterogeneous, possibly due to the low rate of complete response after standard induction therapy in each individual study. We, therefore, performed two types of meta-analyses, one based on the p-values reported for these associations in the individual studies, and one based on the primary response and outcome data provided in the individual studies. Both meta-analyses indicated highly significant associations between maximal response (complete response/near complete response/very good partial response) during or after HDT/SCT and long-term outcomes (overall survival and event-free/progression-free survival). Both meta-analyses also provided evidence of highly significant associations between maximal response following induction therapy and long-term outcomes (overall survival and event-free/progression-free survival).

Key words: long-term survival, progression-free survival, high-dose therapy, multiple myeloma.

This article has been cited by other articles:

				M. Roussel, P. Moreau, A. Huynh, J.-Y. Mary, C. Danho, D. Caillot, C. Hulin, C. Fruchart, G. Marit, B. Pegourie, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM) Blood, January 7, 2010; 115(1): 32 - 37. [Abstract] [Full Text] [PDF]

				H. Ludwig, M. Beksac, J. Blade, M. Boccadoro, J. Cavenagh, M. Cavo, M. Dimopoulos, J. Drach, H. Einsele, T. Facon, et al. Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective Oncologist, January 1, 2010; 15(1): 6 - 25. [Abstract] [Full Text] [PDF]

				A. K. Stewart, P. G. Richardson, and J. F. San-Miguel How I treat multiple myeloma in younger patients Blood, December 24, 2009; 114(27): 5436 - 5443. [Abstract] [Full Text] [PDF]

				J.-L. Harousseau, H. Avet-Loiseau, M. Attal, C. Charbonnel, F. Garban, C. Hulin, M. Michallet, T. Facon, L. Garderet, G. Marit, et al. Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials J. Clin. Oncol., December 1, 2009; 27(34): 5720 - 5726. [Abstract] [Full Text] [PDF]

				M. Cavo, L. Pantani, P. Tacchetti, M. C. Pallotti, A. Brioli, A. Petrucci, E. Zamagni, and P. Tosi Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies J. Clin. Oncol., November 10, 2009; 27(32): e186 - e187. [Full Text] [PDF]

				M. Cavo, F. Di Raimondo, E. Zamagni, F. Patriarca, P. Tacchetti, A. F. Casulli, S. Volpe, G. Perrone, A. Ledda, M. Ceccolini, et al. Short-Term Thalidomide Incorporated Into Double Autologous Stem-Cell Transplantation Improves Outcomes in Comparison With Double Autotransplantation for Multiple Myeloma J. Clin. Oncol., October 20, 2009; 27(30): 5001 - 5007. [Abstract] [Full Text] [PDF]

				A. J. Jakubowiak, T. Kendall, A. Al-Zoubi, Y. Khaled, S. Mineishi, A. Ahmed, E. Campagnaro, C. Brozo, T. Braun, M. Talpaz, et al. Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma J. Clin. Oncol., October 20, 2009; 27(30): 5015 - 5022. [Abstract] [Full Text] [PDF]

				J.-L. Harousseau, M. Attal, and H. Avet-Loiseau The role of complete response in multiple myeloma Blood, October 8, 2009; 114(15): 3139 - 3146. [Abstract] [Full Text] [PDF]

				J. F. San-Miguel and M.-V. Mateos How to treat a newly diagnosed young patient with multiple myeloma Hematology, January 1, 2009; 2009(1): 555 - 565. [Abstract] [Full Text] [PDF]

				J. J. Lahuerta, M. V. Mateos, J. Martinez-Lopez, L. Rosinol, A. Sureda, J. de la Rubia, J. Garcia-Larana, R. Martinez-Martinez, M. T. Hernandez-Garcia, D. Carrera, et al. Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival J. Clin. Oncol., December 10, 2008; 26(35): 5775 - 5782. [Abstract] [Full Text] [PDF]

				J.-L. Harousseau Induction Therapy in Multiple Myeloma Hematology, January 1, 2008; 2008(1): 306 - 312. [Abstract] [Full Text] [PDF]